ISSN: 1837-9664Journal of Cancer
Global reach, higher impact
J Cancer 2024; 15(6):1734-1749. doi:10.7150/jca.93023 This issue Cite
Research Paper
Prognostic and chemotherapeutic response prediction by proliferation essential gene signature: Investigating POLE2 in bladder cancer progression and cisplatin resistance
1. Central Laboratory, the Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, China.
2. Department of Pathology, the Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, China.
3. Ganzhou Key Laboratory of Molecular Medicine, the Affiliated Ganzhou Hospital of Nanchang University, Ganzhou, Jiangxi, 341000, China.
4. The Second Clinical Medical School of Fujian Medical University, Quanzhou, Fujian Province, 362000, China.
5. Department of Urology, the Second Affiliated Hospital of Fujian Medical University, No. 34 Zhongshan North Road, Quanzhou 362000, Fujian.
6. The Second Affiliated Hospital of Fujian University of Traditional Chinese Medicine, Fujian-Macao Science and Technology Cooperation Base of Traditional Chinese Medicine-Oriented Chronic Disease Prevention and Treatment, Innovation and Transformation Center, Fujian University of Traditional Chinese Medicine, Fuzhou, 361000, China.
Citation:
Yu L, Lin N, Ye Y, Zhou S, Xu Y, Chen J, Zhuang W, Wang Q. Prognostic and chemotherapeutic response prediction by proliferation essential gene signature: Investigating POLE2 in bladder cancer progression and cisplatin resistance. J Cancer 2024; 15(6):1734-1749. doi:10.7150/jca.93023. https://www.jcancer.org/v15p1734.htm
Other stylesAbstract
Background: Bladder cancer (BLCA) is the most common genitourinary malignancy. Proliferation essential genes (PEGs) are crucial to the survival of cancer cells. This study aimed to build a PEG signature to predict BLCA prognosis and treatment efficacy.
Methods: BLCA PEGs and differentially expressed PEGs were identified using DepMap and TCGA-BLCA datasets, respectively. Based on the prognostic analysis of the differentially expressed PEGs, a PEG model was constructed. Subsequently, we analyzed the relationship between the PEG signature and prognosis of BLCA patients as well as their response to chemotherapy. Finally, we performed random forest analysis to target and functional experiments to validate the most significant PEG which is associated with BLCA progression. CCK-8, invasion, migration, and chemosensitivity assays were performed to assess effects of gene knockdown on BLCA cell proliferation, invasion and migration abilities, and cisplatin chemosensitivity.
Results: We screened 10 prognostic PEGs from 201 differentially expressed PEGs and used them to construct a PEG signature model. Patients with high PEG signature score (PEGs-high) exhibited worse OS and lower sensitivity to chemotherapy than those with PEGs-low. We also found significant correlations between the PEG score and previously defined BLCA molecular subtypes. This suggests that the PEG score may effectively predict the molecular subtypes which have distinct clinical outcomes. Random forest analysis revealed that POLE2 (DNA polymerase epsilon subunit 2) was the most significant PEG differentiating BLCA tissue and normal tissue. Bioinformatic analysis and an immunohistochemistry staining assay confirmed that POLE2 was significantly up-regulated in tumor tissues and was associated with poor survival in BLCA patients. Moreover, POLE2 knockdown inhibited the ability of cell clone formation, proliferation, invasion, immigration and IC50 of cisplatin.
Conclusion: The PEG signature acts as a potential predictor for prognosis and chemotherapy response in BLCA patients. POLE2 is a key PEG and plays a remarkable role in promoting the malignant progression and cisplatin resistance of BLCA.
Keywords: bladder cancer, POLE2, proliferation, tumor promoter, CRISPR-Cas9, bioinformatic analysis
Citation styles
APA
Yu, L., Lin, N., Ye, Y., Zhou, S., Xu, Y., Chen, J., Zhuang, W., Wang, Q. (2024). Prognostic and chemotherapeutic response prediction by proliferation essential gene signature: Investigating POLE2 in bladder cancer progression and cisplatin resistance. Journal of Cancer, 15(6), 1734-1749. https://doi.org/10.7150/jca.93023.
ACS
Yu, L.; Lin, N.; Ye, Y.; Zhou, S.; Xu, Y.; Chen, J.; Zhuang, W.; Wang, Q. Prognostic and chemotherapeutic response prediction by proliferation essential gene signature: Investigating POLE2 in bladder cancer progression and cisplatin resistance. J. Cancer 2024, 15 (6), 1734-1749. DOI: 10.7150/jca.93023.
NLM
Yu L, Lin N, Ye Y, Zhou S, Xu Y, Chen J, Zhuang W, Wang Q. Prognostic and chemotherapeutic response prediction by proliferation essential gene signature: Investigating POLE2 in bladder cancer progression and cisplatin resistance. J Cancer 2024; 15(6):1734-1749. doi:10.7150/jca.93023. https://www.jcancer.org/v15p1734.htm
CSE
Yu L, Lin N, Ye Y, Zhou S, Xu Y, Chen J, Zhuang W, Wang Q. 2024. Prognostic and chemotherapeutic response prediction by proliferation essential gene signature: Investigating POLE2 in bladder cancer progression and cisplatin resistance. J Cancer. 15(6):1734-1749.
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.